| Identification | Back Directory | [Name]
HMR 1098 | [CAS]
261717-22-0 | [Synonyms]
HMR 1098
Clamikalant sodium
WLSSQIOUQLZDJL-UHFFFAOYSA-N | [Molecular Formula]
C19H23ClN3NaO5S2 | [MDL Number]
MFCD28139069 | [MOL File]
261717-22-0.mol | [Molecular Weight]
495.97 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
H2O: 2 mg/mL, clear | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
H2O: 2mg/mL, clear | [InChIKey]
SUEVHDKFEXAKAF-UHFFFAOYSA-M | [SMILES]
[Na]N(CCc2cc(c(cc2)OC)[S](=O)(=O)NC(=S)NC)C(=O)c1c(ccc(c1)Cl)OC |
| Hazard Information | Back Directory | [Uses]
Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia[1]. | [Biological Activity]
HMR-1098 is a potent and selective blocker of the sarcolemmal ATP-sensitive K+ (sarcKATP) channel. HMR 1098 is inhibits Kir6.2/SUR1-composed KATP channels. | [in vivo]
Clamikalant sodium (HMR 1098; 6.0 mg/kg; 5 min prior to EET administration) completely abolishes the cardioprotection produced by epoxyeicosatrienoic acid (EET)[1]. | [References]
[1] Garrett J Gross, et al. Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts. J Mol Cell Cardiol. 2013 Jun;59:20-9. DOI:10.1016/j.yjmcc.2013.02.003
[2] Hai-yan Zhou, et al. Improved myocardial function with supplement of levosimendan to Celsior solution. J Cardiovasc Pharmacol. 2014 Sep;64(3):256-65. DOI:10.1097/FJC.0000000000000115
[3] Xiaohui Zhang, et al. Sarcolemmal ATP-sensitive potassium channel protects cardiac myocytes against lipopolysaccharide-induced apoptosis. Int J Mol Med. 2016 Sep;38(3):758-66. DOI:10.3892/ijmm.2016.2664 |
|
|